WhiteLab Genomics

Santa Claus made his way to our office! Perhaps we lured him all the way from the North Pole with our 𝗔𝗻𝗻𝘂𝗮𝗹 𝗛𝗼𝗹𝗶𝗱𝗮𝘆 𝗢𝗳𝗳𝗶𝗰𝗲 𝗗𝗲𝗰𝗼𝗿𝗮𝘁𝗶𝗻𝗴 𝗖𝗼𝗺𝗽𝗲𝘁𝗶𝘁𝗶𝗼𝗻. Our Paris office is bedazzled with tinsel, snowflakes, twinkle lights... and we even adorned our water bottles with Santa hats! As we celebrate this festive season, we’re also celebrating the 22 new team members who’ve joined us this year. Each one is a 𝗵𝗶𝗱𝗱𝗲𝗻 𝗴𝗲𝗺, adding their unique brilliance to our global team. With every new face, WhiteLab grows even brighter! Congratulations to our 𝗖𝗼𝗺𝗽𝘂𝘁𝗮𝘁𝗶𝗼𝗻𝗮𝗹 𝗕𝗶𝗼𝗹𝗼𝗴𝘆 𝗧𝗲𝗮𝗺 for winning the Office Decorating Competition this year! Their creative efforts and Can-Do Attitude earned them a well-deserved team outing. Wishing everyone a festive and joyful holiday season! 🎁 ✨ 💎

2024 has been a transformative year for us, marked by impactful partnerships, the growth of our talented team, groundbreaking initiatives, and awards that reflect our dedication to excellence. From launching France's Inaugural TechBio Conference to being recognized as Manufacturing Disruptor of the Year by Phacilitate, the year has been truly remarkable. Highlights include meeting President Emmanuel Macron at Davos and expanding our presence to the US with the opening of our Boston office, key milestones that reflect our dedication to driving global innovation and growth. We’re grateful for you — our partners, team, investors, and community — for your unwavering support. Here’s to an even more impactful 2025 ! ✨ 🚀 🔎 Learn more about our work Posters from our latest presentations: https://lnkd.in/g2sJrsiR Press releases and updates: https://lnkd.in/g8hWs798 #techbio #genomicmedicine #ai

Are you going to #JPM2025? Connect with our CEO + Co-Founder David Del Bourgo and our Head of Partnerships Nathan Lee to learn more about how we optimize the use of biological data-guided rational design and AI to predict the best molecular constructs in pre-clinical genomic medicine. We look forward to connecting with several of our partners, investors, collaborators, and more! See you soon 👋

📣 Join Timothé CYNOBER (Pharm D.) and Robin Eggert-Griscelli for the 𝗔𝗰𝗰𝗲𝗹𝗲𝗿𝗮𝘁𝗶𝗻𝗴 𝗦𝘁𝗮𝗿𝘁𝘂𝗽 𝗜𝗺𝗽𝗮𝗰𝘁: 𝗧𝗵𝗲 𝗣𝗼𝘄𝗲𝗿 𝗼𝗳 𝗛𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 𝗘𝗰𝗼𝘀𝘆𝘀𝘁𝗲𝗺𝘀 webinar, hosted by Future4Care Friday, December 20 at Noon! They’ll discuss how Future4Care helps start-ups make real-world impact with open collaboration and strategic partnerships, impactful networking events, and new market opportunities. 🚀 This year, Future4Care played a pivotal role in the success of our inaugural 𝗧𝗲𝗰𝗵𝗕𝗶𝗼 𝗙𝗿𝗮𝗻𝗰𝗲 𝗖𝗼𝗻𝗳𝗲𝗿𝗲𝗻𝗰𝗲—the first in France to unite TechBio organizations, leaders, and investors. We’re immensely proud to call Future4Care home. Being part of such a supportive and vibrant ecosystem empowers us to advance our mission! 🌟 Register here: https://shorturl.at/dkGhh

Our CEO + Co-Founder David Del Bourgo was featured in Labiotech.eu! “The industry rebounded from broader economic challenges in recent years, including macroeconomic instability. The focus has been on innovation-driven growth, with significant advancements in gene editing, cell and gene therapies, and AI-driven drug discovery. As of Q3 2024, a total of 32 gene therapies and 34 RNA therapies have been approved, according to the American Society of Gene & Cell Therapy and Cell Therapy (ASGCT), underscoring the rapid growth and regulatory progress in these advanced therapeutic modalities.” Great article by Jules ADAM on what biotech industry trends are shaping the industry!

Another powerhouse has joined our team! Let's give a warm welcome to Patrice VIDAL, our new 𝗛𝗲𝗮𝗱 𝗼𝗳 𝗘𝗮𝗿𝗹𝘆 𝗣𝗿𝗲𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵. ✨ 🚀 𝗣𝗮𝘁𝗿𝗶𝗰𝗲 𝗩𝗶𝗱𝗮𝗹, 𝗣𝗵.𝗗 brings a decade of expertise in gene therapies focusing on discovery and preclinical research targeting multiple tissues, particularly through the design and optimization of AAV-based vectors. Throughout his career, he has played a pivotal role in developing therapies for rare genetic diseases and takes pride in knowing that his work benefits patients’ lives. Driven by a passion for science, he excels at innovating and solving complex challenges in collaborative environments. He is motivated by the firm belief that scientific breakthroughs can lead to tangible benefits for patients, which adds profound meaning to the work he and his team do. "𝘐’𝘮 𝘨𝘦𝘯𝘶𝘪𝘯𝘦𝘭𝘺 𝘦𝘹𝘤𝘪𝘵𝘦𝘥 𝘵𝘰 𝘫𝘰𝘪𝘯 𝘞𝘩𝘪𝘵𝘦𝘓𝘢𝘣 𝘎𝘦𝘯𝘰𝘮𝘪𝘤𝘴 𝘣𝘦𝘤𝘢𝘶𝘴𝘦 𝘰𝘧 𝘵𝘩𝘦 𝘱𝘰𝘸𝘦𝘳𝘧𝘶𝘭 𝘪𝘯𝘵𝘦𝘳𝘴𝘦𝘤𝘵𝘪𝘰𝘯 𝘰𝘧 𝘢𝘳𝘵𝘪𝘧𝘪𝘤𝘪𝘢𝘭 𝘪𝘯𝘵𝘦𝘭𝘭𝘪𝘨𝘦𝘯𝘤𝘦 𝘢𝘯𝘥 𝘨𝘦𝘯𝘰𝘮𝘪𝘤 𝘮𝘦𝘥𝘪𝘤𝘪𝘯𝘦, 𝘸𝘩𝘪𝘤𝘩 𝘩𝘢𝘴 𝘵𝘩𝘦 𝘱𝘰𝘵𝘦𝘯𝘵𝘪𝘢𝘭 𝘵𝘰 𝘳𝘦𝘷𝘰𝘭𝘶𝘵𝘪𝘰𝘯𝘪𝘻𝘦 𝘱𝘢𝘵𝘪𝘦𝘯𝘵 𝘤𝘢𝘳𝘦. 𝘛𝘩𝘦 𝘶𝘴𝘦 𝘰𝘧 𝘈𝘐 𝘵𝘰 𝘧𝘢𝘴𝘵-𝘵𝘳𝘢𝘤𝘬 𝘵𝘩𝘦 𝘥𝘦𝘷𝘦𝘭𝘰𝘱𝘮𝘦𝘯𝘵 𝘰𝘧 𝘴𝘢𝘧𝘦𝘳 𝘢𝘯𝘥 𝘮𝘰𝘳𝘦 𝘦𝘧𝘧𝘪𝘤𝘪𝘦𝘯𝘵 𝘵𝘳𝘦𝘢𝘵𝘮𝘦𝘯𝘵𝘴 𝘪𝘴 𝘵𝘳𝘶𝘭𝘺 𝘨𝘳𝘰𝘶𝘯𝘥𝘣𝘳𝘦𝘢𝘬𝘪𝘯𝘨. 𝘐 𝘭𝘰𝘰𝘬 𝘧𝘰𝘳𝘸𝘢𝘳𝘥 𝘵𝘰 𝘤𝘰𝘭𝘭𝘢𝘣𝘰𝘳𝘢𝘵𝘪𝘯𝘨 𝘸𝘪𝘵𝘩 𝘢 𝘵𝘢𝘭𝘦𝘯𝘵𝘦𝘥 𝘵𝘦𝘢𝘮 𝘵𝘰 𝘣𝘭𝘦𝘯𝘥 𝘪𝘯-𝘴𝘪𝘭𝘪𝘤𝘰 𝘮𝘰𝘥𝘦𝘭𝘴 𝘸𝘪𝘵𝘩 𝘩𝘢𝘯𝘥𝘴-𝘰𝘯 𝘳𝘦𝘴𝘦𝘢𝘳𝘤𝘩. 𝘛𝘰𝘨𝘦𝘵𝘩𝘦𝘳, 𝘸𝘦’𝘭𝘭 𝘱𝘶𝘴𝘩 𝘵𝘩𝘦 𝘣𝘰𝘶𝘯𝘥𝘢𝘳𝘪𝘦𝘴 𝘰𝘧 𝘸𝘩𝘢𝘵’𝘴 𝘱𝘰𝘴𝘴𝘪𝘣𝘭𝘦 𝘪𝘯 𝘨𝘦𝘯𝘰𝘮𝘪𝘤 𝘮𝘦𝘥𝘪𝘤𝘪𝘯𝘦.”

🚀 Honored to announce that WhiteLab Genomics is in the Sifted 250 Leaderboard of Europe’s 🇪🇺 fastest-growing startups 🚀 ! This recognition places us among a select group of visionary companies redefining industries and shaping the future of global innovation. It reflects not only our growth but also the transformative impact of cutting-edge #AI on #genomic #medicine. As the Sifted 250 report highlights: "This ranking represents more than growth—it’s a testament to the innovation, resilience, and entrepreneurial spirit that define Europe. These companies demonstrate the agility and vision necessary to thrive in a dynamic global economy." Thank you to our team, partners, investors, and supporters who have made this milestone possible. Let's keep building the future, together! #TechBio #Sifted250 #Deeptech #FrenchTech https://lnkd.in/eu8ywMrB

✨ 𝗠𝗼𝗺𝗲𝗻𝘁𝘀 𝘁𝗵𝗮𝘁 𝗠𝗮𝘁𝘁𝗲𝗿: 𝗟𝗮 𝗖𝗼𝘂𝗿𝘀𝗲 𝗱𝗲𝘀 𝗟𝘂𝗺𝗶𝗲𝗿𝗲𝘀! ✨ Our team lit up the night last month and joined 15,000 light-bearers across France to support the fight against disease. Taking part in such a meaningful event perfectly aligns with our 𝗖𝗼𝗿𝗲 𝗩𝗮𝗹𝘂𝗲𝘀 𝗼𝗳 𝗖𝗮𝗿𝗲 𝗮𝗻𝗱 𝗖𝗮𝗻-𝗗𝗼 𝗔𝘁𝘁𝗶𝘁𝘂𝗱𝗲. These values drive us to step up, take action, and contribute to causes that make a real difference. Since 2010, 𝗟𝗮 𝗖𝗼𝘂𝗿𝘀𝗲 𝗱𝗲𝘀 𝗟𝘂𝗺𝗶𝗲𝗿𝗲𝘀 has united individuals, families, friends, and companies like ours to raise €1.5 million in donations, supporting research and charitable organizations such as Institut Curie, Centre Hospitalier Universitaire de Bordeaux, Fondation Toulouse Cancer Santé, and Fédération Française des Diabétiques. A huge thank you to the organizers and all participants for making this event so impactful and unforgettable! Together, we took steps—literally and figuratively—towards a brighter and healthier future.

Our CEO, David Del Bourgo, will join a stellar lineup of industry experts at the upcoming Biotechnology Innovation Organization Webinar, "Partnering & Partying with a Purpose" at 1PM EST on Thursday December 5th, 2024. This webinar dives into insider tips, must-attend events, and smart tools to elevate your networking game at #JPM2025, plus a live Q&A with the panel. Don’t miss out! Other panelists include: ⭐ Ali Ardakani, Founder & Managing Director of Novateur Ventures Inc. ⭐ Hemmie Chang, Partner and Head of Boston Office at Arnold & Porter ⭐ Donna L. LaVoie, CEO and Founder of LaVoieHealthScience Additionally, the event will be hosted and moderated by Mackensie V., Vice President of Partnering at Biotechnology Innovation Organization. Register here! https://lnkd.in/dXccJHfg

Elated to announce the arrival of three new team members in our Computational Biology team! Their expertise and unique perspectives will add a new layer of insight as we work together to shape the future of genomic medicine. 🚀 ✨  Mériadec Morrier holds dual M2 degrees from École Polytechnique (Computer Science and Biology), where he discovered his passion for computational biology, and EPFL in Lausanne, Switzerland (Biological Data Science). For his master's thesis, he interned at Novigenix SA, where he contributed to advancing innovative methods and precise metrics to enhance the biomarker discovery process. His Masterʼs thesis focused on combining differential expression analysis results from bulk RNA-seq data to identify reliable biomarkers and the assessment of contributions specific to each sample. As he completed his studies at the intersection of biology and data analysis, joining WhiteLab enables him to continue to further integrate the two fields, with the added bonus of the most beautiful of goals: to accelerate the development of treatments for tomorrow's patients! 💫  Rafi Chalhoub obtained his Master’s degree in Bioinformatics, specializing in software development and data analysis, from Aix-Marseille University. During his Master's, Rafi gained valuable insights into the integration of biological data with computational power, developing a particular fascination for machine learning. His previous experience includes internships at the Laboratoire de Neurosciences Cognitives (LNC) in Marseille and the Cancer Research Center of Marseille (CRCM), where he focused on application and pipeline development as well as genomic data analysis. Additionally, he earned his Bachelor's degree in Biology from the Lebanese University of Beirut. Having lived in Qatar and Saudi Arabia, Rafi brings a multicultural perspective to his work. He’s thrilled to join the team and eager to apply machine learning to discovering and designing new genomic medicines that drive scientific advancements. 🌟  Sophia Houhamdi currently attends ETH Zürich, where she is pursuing a Master’s degree in Computational Biology and Bioinformatics. She also holds a Diplôme d’Ingénieur in Applied Mathematics from École Polytechnique in Paris. With a strong background in machine learning, she participated in various data science projects that bridged the gap between biology and computer science. Sophia’s prior research experience includes developing optimization frameworks for public health at Harvard University. She is passionate about leveraging her skills to advance healthcare and finds the opportunity to contribute to AI-driven genomic medicine at WhiteLab Genomics truly inspiring.